



Lymphoma Audit

NNHLA, Clinical Effectiveness Unit


Royal College of Surgeons of England 38-43 Lincoln's Inn Fields London WC2A 3PE

E: NHLaudit@rcseng.ac.uk T: 020 73044787 Y NNHLA\_NATCAN

# **NNHLA Newsletter, Summer 2023**

# Want to find out more?

The NNHLA is part of the National Cancer Audit Collaborating Centre (NATCAN). If you want to find out more about NATCAN visit our <u>new website</u>. If you would like to receive regular updates send us an email <u>NATCAN@rcseng.ac.uk</u>



# Announcing the launch of NNHLA!

We are excited to announce the launch of the new National Non-Hodgkin Lymphoma Audit (NNHLA) as part of the <u>National Cancer Audit</u> <u>Collaborating Centre</u>, which is hosted by the Clinical Effectiveness Unit at the Royal College of Surgeons and commenced in October 2022. NATCAN is a new centre of excellence in cancer audits. The NNHLA is one of six new national audits, which have been commissioned by the Healthcare Quality Improvement Partnership (HQIP), on behalf of NHS England and the Welsh Government. The audit aims to support NHS services to increase the consistency and access to treatments and to stimulate improvements in the quality of care, leading to better outcomes for patients. More information about the NNHLA can be found <u>here</u>.

#### Our data use

In line with other national audits, the NNHLA will not 'collect' clinical data and instead, will utilise nationally mandated flows of data from cancer patients to the National Disease Registration Service (NDRS), NHSE, the Wales Cancer Network and Public Health Wales.

For English patients, the NNHLA has access to the Gold Standard dataset and rapid cancer registration dataset (RCRD). The RCRD allows timely and frequent (at least quarterly) reporting to cancer services. The Gold standard dataset provides a richer description of cancer patients but is less timely presently. During the first year, we will be exploring how to use these datasets to define robust indicators that can support the NNHLA's quality improvement initiatives and decision making by cancer services. In the Autumn, we will publish a minimum dataset, comprising relevant data items for each cancer site, which hospitals can check are being completed and submitted to the NDRS or the Wales Cancer Network.

For more information see our FAQ page here.

## **Our Clinical Leads**

Representing the British Society of Haematology, we are delighted to have two experienced Clinical Leads onboard, as part of our Project Team. •**Dr David Cutter** - Consultant Clinical Oncologist, Oxford Cancer Centre & Associate Professor, Nuffield Department of Population Health, University of Oxford.

•**Dr Cathy Burton** – Consultant Haematologist, Leeds Teaching Hospitals NHS Trust & Haematological Malignancy Diagnostic Service, Leeds. Watch this <u>short film</u> to hear Cathy talk about the NNHLA and key considerations in the design of this new audit.

## **Blood Cancer UK**

"At <u>Blood Cancer UK</u>, we welcome the launch of the new audit into non-Hodgkin's lymphoma. This audit offers a great opportunity to improve the treatment, care, and support

for people with this type of blood cancer. We're looking forward to supporting this work to help achieve better and more consistent outcomes for people across England and Wales." Helen Rowntree, CEO, Blood Cancer Uk





This email was sent to you by NNHLA part of NATCAN, Royal College of Surgeons of England, 38-43 Lincoln's Inn Fields, London WC2A. To ensure continued receipt of our emails please add us to your address book or safe list. In accordance with the General Data Protection Regulation (GDPR), we are committed to protecting your privacy. If you wish to know more please access the NATCAN privacy policy. If you wish to unsubscribe from all NNHLA email communications please click here. © RCSEng 2023, Registered Charity No. 212808